导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.63% | 1508/3266 |
| 近一周 | -2.05% | 2206/3690 |
| 近一月 | -1.28% | 721/3663 |
| 近一季 | -4.99% | 1360/3534 |
| 近半年 | -9.04% | 2450/3357 |
| 近一年 | 4.50% | 1265/3056 |
| 近两年 | 31.52% | 1623/2167 |
| 近三年 | 22.45% | 996/1638 |
| 成立以来 | 101.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.51% 716/4961 |
1.53% 3012/5312 |
- - |
- - |
| 2025 | 7.38% 2927/4813 |
-4.37% 3169/3635 |
1.15% 2442/4076 |
7.46% 3449/4524 |
3.30% 701/4813 |
| 2024 | 20.66% 450/3463 |
9.73% 117/2808 |
2.20% 377/3014 |
8.13% 2769/3129 |
-0.51% 1446/3463 |
| 2023 | 8.18% 130/2656 |
16.97% 186/2280 |
1.12% 236/2385 |
-3.25% 882/2515 |
-5.47% 1366/2655 |
| 2022 | -12.45% 285/2207 |
-10.92% 456/1919 |
2.74% 1261/2016 |
-9.72% 301/2113 |
5.96% 406/2208 |
| 2021 | 33.07% 53/1822 |
4.03% 162/1255 |
5.18% 820/1330 |
19.63% 49/1466 |
1.66% 844/1822 |
| 2020 | 16.89% 771/1250 |
-6.31% 478/1028 |
0.05% 1009/1067 |
12.21% 401/1164 |
11.13% 562/1184 |
| 2019 | - - |
- - |
- - |
- - |
-0.97% 894/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国央企创新ETF VS. 长安沪深300非周期A(740101) |